SCHEMBL2928221

SCHEMBL2928221

O=C(Nc1ccc2nc(CN3CCCCC3)ccc2c1)N1CCC(c2ccc(Cl)cc2)CC1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 7/20 0.72
HTR2C P28335 2/20 0.72
FAAH O00519 4/20 0.59
MAPT P10636 5/20 0.53
TP53 P04637 4/20 0.53
LMNA P02545 3/20 0.48
NPC1 O15118 1/20 0.48
NFKB1 P19838 1/20 0.48
RAB9A P51151 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
NAMPT P43490 1/20 0.45
MLLT1 Q03111 1/20 0.45
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45
HSD17B10 Q99714 1/20 0.45
ALOX5 P09917 1/20 0.44
SMO Q99835 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2925581 0.99 MCHR1 (0.73) MCHR1HTR2CFAAHMAPTTP53
SCHEMBL2928424 0.91 MCHR1 (0.72) MCHR1HTR2CFAAHMAPTLMNA
SCHEMBL2924965 0.91 MCHR1 (0.72) MCHR1HTR2CFAAHMAPTTP53
SCHEMBL2925134 0.90 MCHR1 (0.73) MCHR1HTR2CFAAHMAPTTP53
SCHEMBL2918912 0.90 MCHR1 (0.73) MCHR1HTR2CFAAHMAPTLMNA
SCHEMBL2926365 0.90 MCHR1 (0.72) MCHR1HTR2CFAAHMAPTTP53
SCHEMBL2928268 0.88 MCHR1 (0.73) MCHR1HTR2CFAAHMAPTSMN1; SMN2
SCHEMBL2926870 0.86 MCHR1 (0.59) MCHR1HTR2CFAAHMAPTTP53
SCHEMBL2926868 0.86 MCHR1 (0.59) MCHR1HTR2CFAAHMAPTTP53
SCHEMBL2925899 0.86 MCHR1 (0.75) MCHR1HTR2CFAAHMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1285651-B1 MELANIN CONCENTRATING HORMONE ANTAGONISTS TAKEDA PHARMACEUTICAL (JP) 2010-09-01 EP disclosed
EP-1285651-B1 MELANIN CONCENTRATING HORMONE ANTAGONISTS TAKEDA PHARMACEUTICAL (JP) 2010-09-01 EP disclosed
US-6930185-B2 Melanin-concentrating hormone antagonist TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-16 US disclosed
US-20040077628-A1 Melanin-concentrating hormone antagonist TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-22 US disclosed
EP-1285651-A1 MELANIN CONCENTRATING HORMONE ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 2003-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077628-A1 Melanin-concentrating hormone antagonist MCHR1, MC1R, MCHR2 MCHR1 1/4885HTR2C 107/4885FAAH 1031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.